HARMONY BIOSCIENCES HOLDINGS, INC. Investing Cash Flow
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) reported Investing Cash Flow of -$315.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-04
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$131.50M.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$183.65M, a 7875.02% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$17.63M.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$4.79M, a 742.82% decline year-over-year.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$39.65M.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$67.48M.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$46.44M.
- HARMONY BIOSCIENCES HOLDINGS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$141.83M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$131.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$315.15M 10-Q · filed 2026-08-04 | -$332.78M derived: sum of 3 quarters · filed 2026-08-04 | -$337.57M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$183.65M 10-Q · filed 2026-05-07 | -$201.28M derived: sum of 2 quarters · filed 2026-05-07 | -$206.07M derived: sum of 3 quarters · filed 2026-05-07 | -$225.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$17.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$22.42M derived: sum of 2 quarters · filed 2026-02-24 | -$42.01M derived: sum of 3 quarters · filed 2026-08-04 | -$39.65M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$4.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$24.38M derived: sum of 2 quarters · filed 2026-08-04 | -$22.02M 10-Q · filed 2025-11-04 | -$29.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$19.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$17.23M 10-Q · filed 2026-08-04 | -$24.41M derived: sum of 3 quarters · filed 2026-08-04 | -$23.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.36M 10-Q · filed 2026-05-07 | -$4.83M derived: sum of 2 quarters · filed 2026-05-07 | -$4.08M derived: sum of 3 quarters · filed 2026-05-07 | -$58.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$6.44M derived: sum of 2 quarters · filed 2026-02-24 | -$61.30M derived: sum of 3 quarters · filed 2026-02-24 | -$67.48M 10-K · filed 2026-02-24 |
| 2024-09-30 | $745.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$54.11M derived: sum of 2 quarters · filed 2025-11-04 | -$60.30M 10-Q · filed 2025-11-04 | -$96.36M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$54.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$61.04M 10-Q · filed 2025-08-05 | -$97.11M derived: sum of 3 quarters · filed 2026-02-24 | -$97.92M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$6.19M 10-Q · filed 2025-05-06 | -$42.25M derived: sum of 2 quarters · filed 2026-02-24 | -$43.06M derived: sum of 3 quarters · filed 2026-02-24 | -$50.84M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$36.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$36.88M derived: sum of 2 quarters · filed 2026-02-24 | -$44.65M derived: sum of 3 quarters · filed 2026-02-24 | -$46.44M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$813.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | -$8.58M derived: sum of 2 quarters · filed 2024-10-29 | -$10.37M 10-Q · filed 2024-10-29 | -$57.27M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$7.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$9.56M 10-Q · filed 2024-08-06 | -$56.46M derived: sum of 3 quarters · filed 2025-02-25 | -$88.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$1.79M 10-Q · filed 2024-04-30 | -$48.69M derived: sum of 2 quarters · filed 2025-02-25 | -$81.13M derived: sum of 3 quarters · filed 2025-02-25 | -$103.58M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$46.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$79.34M derived: sum of 2 quarters · filed 2025-02-25 | -$101.79M derived: sum of 3 quarters · filed 2025-02-25 | -$141.83M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$32.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$54.89M derived: sum of 2 quarters · filed 2023-10-31 | -$94.94M 10-Q · filed 2023-10-31 | -$94.94M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$22.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$62.49M 10-Q · filed 2023-08-01 | -$62.49M derived: sum of 3 quarters · filed 2024-02-22 | -$62.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$40.05M 10-Q · filed 2023-05-02 | -$40.05M derived: sum of 2 quarters · filed 2024-02-22 | -$40.14M derived: sum of 3 quarters · filed 2024-02-22 | -$40.34M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$93.00K derived: sum of 2 quarters · filed 2024-02-22 | -$294.00K derived: sum of 3 quarters · filed 2024-02-22 | -$100.30M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$294.00K derived: sum of 2 quarters · filed 2022-11-01 | -$100.30M 10-Q · filed 2022-11-01 | -$102.30M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$100.20M 10-Q · filed 2022-08-02 | -$102.20M derived: sum of 3 quarters · filed 2023-02-21 | -$102.20M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | -$100.00M 10-Q · filed 2022-05-03 | -$102.00M derived: sum of 2 quarters · filed 2023-02-21 | -$102.00M derived: sum of 3 quarters · filed 2023-02-21 | |
| 2020-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | -$2.00M derived: sum of 2 quarters · filed 2023-02-21 | -$2.00M 10-K · filed 2023-02-21 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$2.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$2.00K 10-Q · filed 2021-08-10 | |||
| 2019-12-31 | -$77.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$127.15M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$50.11M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |